The COVID-19 pandemic exposed fragility in global healthcare supply chains, particularly for critical oncology drugs like bevacizumab. Disruptions in manufacturing, shipping, and clinic access delayed treatments for thousands, underscoring the need for resilient supply systems. Biosimilar bevacizumab, with its decentralized production potential, is now playing a pivotal role in restoring stability. By enabling local manufacturing—especially in regions with high cancer burdens—biosimilars reduce reliance on global supply networks, ensuring consistent access even during crises.

During the pandemic, biosimilar adoption accelerated in several regions. In Spain, where hospital visits were restricted, pharmacies prioritized biosimilars with longer shelf lives and easier storage, reducing supply chain strain. Similarly, in India, local biosimilar production prevented shortages when international shipping routes were suspended. These experiences have solidified payers’ commitment to biosimilars; the EU’s 2023 “Resilience in Pharma” initiative explicitly encourages biosimilar manufacturing as a supply chain safeguard.

Yet, post-pandemic challenges remain. Geopolitical tensions, such as the Russia-Ukraine conflict, have disrupted raw material supplies (e.g., glass for vials, enzymes for production), raising costs for biosimilar manufacturers. Additionally, labor shortages in manufacturing facilities—exacerbated by pandemic-related attrition—have slowed production in some regions. To address these, firms are diversifying suppliers and investing in automation; Biocon, for example, has implemented AI-driven quality control systems to reduce dependence on manual labor.

To plan for resilience, stakeholders need insights into supply chain dynamics. The post-pandemic market recovery report from Market Research Future explores supply chain vulnerabilities, regional manufacturing strengths, and policy responses, empowering companies to build robust, future-ready systems. Biosimilar bevacizumab is not just a therapy—it’s a linchpin for healthcare system resilience in an unpredictable world.